Mirador Capital Partners LP boosted its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Rating) by 81.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 62,511 shares of the biotechnology company’s stock after buying an additional 28,007 shares during […]
Nwam LLC lowered its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Rating) by 10.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,741 shares of the biotechnology company’s stock after selling 2,000 shares during the quarter. Nwam LLC’s […]
Avidity Biosciences, Inc. (NASDAQ:RNA – Get Rating)’s share price was down 6.7% during trading on Thursday . The stock traded as low as $16.12 and last traded at $16.17. Approximately 533,509 shares were traded during mid-day trading, a decline of 48% from the average daily volume of 1,026,718 shares. The stock had previously closed at […]
TD Asset Management Inc. cut its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA – Get Rating) by 3.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 143,086 shares of the biotechnology company’s stock after selling 5,258 shares during the period. TD Asset […]